AVR 4.44% $14.00 anteris technologies ltd

Clinical trials, page-16

  1. 2,158 Posts.
    lightbulb Created with Sketch. 802
    If we are on our game we would be on the front foot getting in contact with Bain Capital and at least another half a dozen investors that backed Jenavalve.
    They may be looking for somewhere to park a few hundred million from their realised investment.
    Would be nice to have backup and an alternative to the NASDAQ, or adding some pent up demand for the IPO by investors that obviously understand the space.

    In 2022 Jenavalve raised US$100m to complete their pivotal trial through these investors.
 
watchlist Created with Sketch. Add AVR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.